NASDAQ:ALGS Aligos Therapeutics (ALGS) Stock Price, News & Analysis $0.54 0.00 (0.00%) (As of 07/26/2024 ET) Add Compare Share Share Today's Range$0.51▼$0.5550-Day Range$0.35▼$0.6752-Week Range$0.35▼$1.20Volume55,039 shsAverage Volume372,341 shsMarket Capitalization$42.17 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Aligos Therapeutics alerts: Email Address Aligos Therapeutics MarketRank™ Stock AnalysisAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy0.32% of Shares Sold ShortDividend StrengthN/ASustainability-0.80Upright™ Environmental ScoreNews Sentiment0.88Based on 3 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.73) to ($0.71) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.53 out of 5 starsMedical Sector292nd out of 936 stocksBiological Products, Except Diagnostic Industry40th out of 154 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Aligos Therapeutics.Read more about Aligos Therapeutics' stock forecast and price target. Previous Next 5.0 Short Interest Percentage of Shares Shorted0.32% of the outstanding shares of Aligos Therapeutics have been sold short.Short Interest Ratio / Days to CoverAligos Therapeutics has a short interest ratio ("days to cover") of 0.6, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Aligos Therapeutics has recently decreased by 88.50%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAligos Therapeutics does not currently pay a dividend.Dividend GrowthAligos Therapeutics does not have a long track record of dividend growth. Previous Next 4.8 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreAligos Therapeutics has received a 76.60% net impact score from Upright. The largest positive contribution comes from its "Creating knowledge" impact, which is false driven by its "Clinical research services of the circulatory system", "Clinical research services for metabolic diseases", and "Basic medical research services for physical health" products. See details.Environmental SustainabilityThe Environmental Impact score for Aligos Therapeutics is -0.80. Previous Next 3.3 News and Social Media Coverage News SentimentAligos Therapeutics has a news sentiment score of 0.88. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Aligos Therapeutics this week, compared to 1 article on an average week.Search InterestOnly 1 people have searched for ALGS on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows2 people have added Aligos Therapeutics to their MarketBeat watchlist in the last 30 days. Previous Next 2.5 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aligos Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders16.50% of the stock of Aligos Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions60.43% of the stock of Aligos Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Aligos Therapeutics' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Aligos Therapeutics are expected to grow in the coming year, from ($0.73) to ($0.71) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aligos Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aligos Therapeutics is -0.42, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAligos Therapeutics has a P/B Ratio of 0.44. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Aligos Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Crypto Swap Profits625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetched, but results like this are within reach with the right knowledge and timing in the altcoin market. Plus, you’ll get $10 in real Bitcoin when you stay to the end of the call and take a short quiz.>> Dive into the Workshop Here About Aligos Therapeutics Stock (NASDAQ:ALGS)Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapeutics to address unmet medical needs in viral and liver diseases. Its drug candidate, ALG-055009, a small molecule THR-ß agonist that is in the Phase 2a clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). The company also develops ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB); and ALG-125755, a siRNA drug candidate, which is in Phase I clinical trial for the treatment of CHB. In addition, it develops ALG-097558, which is in Phase 2 clinical trial for the treatment of coronavirus. The company has entered into license and research collaboration agreement with Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH; license agreement with Emory University to provide hepatitis B virus capsid assembly modulator technology; license agreement with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; and research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors. Aligos Therapeutics, Inc. was incorporated in 2018 and is headquartered in South San Francisco, California.Read More ALGS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ALGS Stock News HeadlinesJuly 22, 2024 | globenewswire.comAligos Therapeutics Announces Clinical Collaboration with Xiamen Amoytop Biotech Co., Ltd.July 10, 2024 | globenewswire.comAligos Therapeutics to Host KOL Event to Discuss the Positive Phase 1b Data from ALG-000184 for the Treatment of CHBJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.June 5, 2024 | globenewswire.comAligos Therapeutics Presents Positive Data at the EASL Congress 2024May 22, 2024 | globenewswire.comAligos Therapeutics Announces Six Abstracts Accepted for Presentation at EASL 2024May 21, 2024 | globenewswire.comAligos Therapeutics Announces the Completion of Enrollment in the ALG-055009 Phase 2a HERALD Study for the Treatment of MASHMay 17, 2024 | markets.businessinsider.comPiper Sandler Keeps Their Buy Rating on Aligos Therapeutics (ALGS)May 10, 2024 | markets.businessinsider.comHold Rating on Aligos Therapeutics Amidst Clinical Trials and Financial StabilityJuly 27, 2024 | Unstoppable Prosperity (Ad)“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 special FREE Gifts during the event.May 9, 2024 | finance.yahoo.comAligos Therapeutics First Quarter 2024 Earnings: US$0.22 loss per share (vs US$0.54 loss in 1Q 2023)May 7, 2024 | investorplace.comALGS Stock Earnings: Aligos Therapeutics Misses EPS for Q1 2024May 7, 2024 | finance.yahoo.comAligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial ResultsMay 7, 2024 | finance.yahoo.comAligos Therapeutics Reports Recent Business Progress and First Quarter 2024 Financial ResultsApril 30, 2024 | finance.yahoo.comAligos Therapeutics to Announce 1st Quarter 2024 Financial Results on May 7, 2024April 25, 2024 | globenewswire.comAligos Therapeutics Presents Positive Clinical Data at ESCMID 2024 from the ALG-097558 Phase 1 StudyApril 25, 2024 | finance.yahoo.comAligos Therapeutics Mourns the Passing of MASH Industry Leader Stephen A. Harrison, MDApril 9, 2024 | finance.yahoo.comAligos Therapeutics to Participate in the Piper Sandler Spring Biopharma Symposium 2024April 3, 2024 | finance.yahoo.comAligos Therapeutics Announces First Subjects Dosed in the Phase 2a HERALD Study of ALG-055009 in MASH SubjectsSee More Headlines Receive ALGS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Aligos Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/07/2024Today7/26/2024Next Earnings (Estimated)8/01/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ALGS CUSIPN/A CIK1799448 Webwww.aligos.com Phone800-466-6059FaxN/AEmployees90Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.28) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-87,680,000.00 Net Margins-783.72% Pretax Margin-777.58% Return on Equity-144.16% Return on Assets-84.50% Debt Debt-to-Equity RatioN/A Current Ratio6.25 Quick Ratio6.25 Sales & Book Value Annual Sales$15.53 million Price / Sales2.72 Cash FlowN/A Price / Cash FlowN/A Book Value$1.23 per share Price / Book0.44Miscellaneous Outstanding Shares78,110,000Free Float65,222,000Market Cap$42.17 million OptionableOptionable Beta2.19 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Lawrence M. Blatt MBA (Age 62)Ph.D., CEO, President & Chairman of the Board Comp: $1.03MDr. Julian A. Symons DPHIL (Age 62)Executive VP & Chief Scientific Officer Comp: $735.51kDr. Matthew W. McClure M.D. (Age 52)Executive VP & Chief Medical Officer Comp: $740.39kKristina EngesethVP and Head of People & CultureDr. Sushmita M. Chanda DABT (Age 57)Ph.D., Executive Vice President & Chief Development Officer Dr. David B. Smith Ph.D.Executive VP & Head of Chemical OperationsDr. Tse-I Lin Ph.D.VP of Early Compound Development & Belgian Site HeadMore ExecutivesKey CompetitorsAssembly BiosciencesNASDAQ:ASMBINmune BioNASDAQ:INMBCardiol TherapeuticsNASDAQ:CRDLKodiak SciencesNASDAQ:KODAdverum BiotechnologiesNASDAQ:ADVMView All CompetitorsInsiders & InstitutionsOpaleye Management Inc.Bought 333,000 shares on 5/29/2024Ownership: 2.087%Acadian Asset Management LLCBought 98,628 shares on 5/10/2024Ownership: 0.870%Carole NuechterleinBought 7,933,601 shares on 10/25/2023Total: $6.03 M ($0.76/share)View All Insider TransactionsView All Institutional Transactions ALGS Stock Analysis - Frequently Asked Questions How have ALGS shares performed this year? Aligos Therapeutics' stock was trading at $0.6640 at the beginning of the year. Since then, ALGS stock has decreased by 18.7% and is now trading at $0.5399. View the best growth stocks for 2024 here. How were Aligos Therapeutics' earnings last quarter? Aligos Therapeutics, Inc. (NASDAQ:ALGS) posted its quarterly earnings results on Tuesday, May, 7th. The company reported ($0.22) earnings per share for the quarter, missing analysts' consensus estimates of ($0.19) by $0.03. The business had revenue of $0.99 million for the quarter. Aligos Therapeutics had a negative net margin of 783.72% and a negative trailing twelve-month return on equity of 144.16%. When did Aligos Therapeutics IPO? Aligos Therapeutics (ALGS) raised $150 million in an IPO on Friday, October 16th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. J.P.Morgan, Jefferies and Piper Sandler served as the underwriters for the IPO and Cantor was co-manager. Who are Aligos Therapeutics' major shareholders? Aligos Therapeutics' top institutional investors include Concourse Financial Group Securities Inc.. View institutional ownership trends. How do I buy shares of Aligos Therapeutics? Shares of ALGS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:ALGS) was last updated on 7/27/2024 by MarketBeat.com Staff From Our Partners625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | Sponsored“Generational Bull Run” IncomingLIVE Cash Flow Workshop Event / Hosted Virtually Weds @ 7PM EST Everyone who attends will also receive 3 sp...Unstoppable Prosperity | SponsoredNext opportunity for crypto millionsThe Bitcoin halving is the #1 creator of "crypto millionaires". That's because historically, every halving has...Crypto 101 Media | Sponsoredtop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)AI was by far the biggest tech investing trend right now. But Ross Givens says the #1 artificial intelligen...Traders Agency | SponsoredThe #1 Crypto for 2024 (3 Cent Coin)Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredDon't Pay a Dime for Marc Lichtenfeld's Top AI PicksUsually, you'd have to plunk down a hefty sum to get your hands on Marc Lichtenfeld's latest income research.....The Oxford Club | SponsoredThe asset beating inflation by 4xCentral Bank Gold Heist In Progress Central banks are buying gold at record rates... and billionaire invest...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Aligos Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Aligos Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
